News
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
BioPorto Diagnostics obtains Quality Management Certification
February 18 2010
TSIS 2010, March 9-13, Munich, Germany
February 18 2010
ToxExpo, March 7-11, Salt Lake City, Utah
February 16 2010
CRITICARE 2010, February 10-14, Hyderabad, India
January 25 2010
Congress calendar 2010
January 11 2010
SCCM Annual Congress, January 9-13, Miami Beach, Florida
January 07 2010
BioPorto Diagnostics and ALPCO Diagnostics enter into partnership
December 02 2009
Product launch: Dog NGAL ELISA Kit (KIT 043)
November 16 2009
MEDICA, November 18-21, Düsseldorf, Germany
November 09 2009
Further expansion of our GLP-1 portfolio: Anti-GLP-1 (Non-amidated (-Arg-Gly) C-terminal specific) antibody
June 10 2009 by Ana Belén Enfedaque Buisán
BioPorto Diagnostics is pleased to announce the launch of a new monoclonal antibody ABS 046-03. The new antibody ABS 046-03 recognizes the C-terminus of non-amidated (-Arg-Gly) GLP-1 and shows a low level of cross-reactivity with C-terminally amidated GLP-1.
The active forms of GLP-1 are potent stimulators of glucose-dependent insulin secretion and GLP-1 receptor agonists are strong drug candidates for the treatment of type 2 diabetes. BioPorto Diagnostics’ GLP-1 antibody portfolio provides useful tools for physiological and pharmaceutical research into the therapy of type 2 diabetes, and, as GLP-1 is also involved in the regulation of food intake, in developing treatments for obesity.
The launch of this new antibody brings BioPorto Diagnostics a step closer to being able to offer a complete GLP-1 antibody portfolio, which currently includes unique antibodies for several different GLP-1 forms and related targets such as Exendin-4.
BioPorto Diagnostics is launching this antibody as a part of the AntibodyShop portfolio and expects to expand the GLP-1 group of antibodies even further in the future.
